Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase

NCT03079505 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT03079505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03079505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase
Lead sponsor
Hamad Medical Corporation
Phase
Phase 3
Overall status
Terminated
Start date
August 3, 2017
Completion date
September 23, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia - chronic phase